Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.075 AUD | -3.85% | 0.00% | +8.70% |
Apr. 17 | Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint | MT |
Apr. 17 | Neurotech International Completes AU$10 Million Capital Raise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
+8.70% | 53.05M | |
-11.41% | 2.95B | |
+2.35% | 190M | |
-14.72% | 84.22M |
- Stock Market
- Equities
- NTI Stock
- News Neurotech International Limited
- Neurotech International Says Considerable Improvement in ASD Patients Treated with NTI164; Shares Decline 9%